« Previous
Next »
Titles
- Alternative pricing models for remdesivir and other potential treatments for COVID-191
- Drug price increases that exceed inflation are costing Medicare Part D billions1
- Drug price moderation in Germany: lessons for U.S. reform efforts1
- Estimated changes to employer-sponsored health insurance premiums due to the drug inflation rebate provision of the Build Back Better Act1
- Getting to lower prescription drug prices: the key drivers of costs and what policymakers can do to address them1
- How state Medicaid programs are managing prescription drug costs: results from a state Medicaid pharmacy survey for state fiscal years 2019 and 20201
- Paying for drugs in Medicare Part D under current law and under proposals to redesign the program1